US › Healthcare

Tscan Therapeutics Inc (TCRX)

US · Healthcare · Biotechnology

$0.74+1.81%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$982,000
Revenue YoY
-54.8%
Net profit
$-28.7M
Profit YoY
+16.0%
EPS
$-0.22
EPS estimate
$-0.16
Net margin
-2,919.1%

EPS came in at -0.22 against a street estimate of -0.16 — a miss of 37.5%.

Key statistics

Market cap
$47.3M
Forward P/E
0.0
P/B
0.50
Book value
$1.61
EPS (TTM)
$-0.96
52-week high
$2.57
52-week low
$0.72
50-day MA
$0.95
200-day MA
$1.13
Beta
1.07

Analyst view

Analysts rate Tscan Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $6.00.

Shareholding

Insiders
0.20%
Institutions
58.30%

Largest institutional holders

FundStake
Lynx1 Capital Management, LP12.27%
Bvf Inc8.51%
Baker Bros Advisors LP4.26%
Vanguard Capital Management, LLC3.30%
BlackRock Inc2.82%
Millennium Management LLC2.23%
Renaissance Technologies Corp2.09%
Deer Management Co. LLC1.91%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Tscan Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.